Cytokinetics Announces Results of BENEFIT-ALS

April 25, 2014

Today, Cytokinetics, Incorporated announced top-line results of BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS). The company plans to issue detailed results at the 66th Annual Meeting of the American Academy of Neurology (AAN) on Tuesday, April 29th at the Pennsylvania Convention Center in Philadelphia, Pa.

According to Cytokinetics, BENEFIT-ALS did not achieve its primary efficacy endpoint, the mean change from baseline in the ALS Functional Rating Scale in its revised form (ALSFRS-R) on tirasemtiv versus placebo. Secondary efficacy analyses of the effect of tirasemtiv on respiratory function and other measures of skeletal muscle function produced mixed results.

For more information, please read the Cytokinetics press release.

Powered by Blackbaud
nonprofit software